Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Epidemiology, Treatment and Prognosis"
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Clinical Neurology".
Deadline for manuscript submissions: 15 June 2023 | Viewed by 7433
Special Issue Editor
Interests: ME/CFS; immunology; infections; drug treatment; prognosis
Special Issue Information
ME/CFS is a highly debilitating condition that simultaneously impacting multiple body systems, and affects a significant portion of the population. It remains poorly understood, and there are few scientifically proven treatments. Much research has focused on possible etiological factors and the precise disturbance that affects mitochondria as well as the immune, endocrine, gastrointestinal and nervous systems. However, while long COVID, with its numerous similarities, has slightly changed the perception and sympathy for people with ME/CFS, it remains rife with prejudice amongst the general population and sadly even amongst healthcare staff. This is despite the obvious suffering of patients and their carers, as well as the substantial burden that this illness has on healthcare resources and the wider economy. Notwithstanding the importance of determining pathogenic mechanisms of ME/CFS symptoms, clinicians and sufferers are eager for knowledge about currently available validated treatment options and the prognosis of this illness. It is hoped that this may reduce the often large amounts of money wasted by patients on untested treatments that have no biochemical or medical mechanisms for improving symptoms.
This Special Issue of JCM has the aim of providing practical knowledge about ME/CFS. A section on the epidemiology of the illness on a global scale in different ethnic groups is included. Authors are encouraged to discuss pathways by which specific treatments work in the context of our present understanding of ME/CFS, and to highlight side effects and limitations. Literature reviews that draw together the different strands of the huge quantity of information on etiologic factors and disease mechanisms and how they produce a delayed worsening of symptoms are most welcome. Original research comparing different treatment strategies will receive the highest priority from the Editorial Office. Research in patient populations which are less frequently discussed such as children and ethnic minorities would also be appreciated.
Dr. Amolak Bansal
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- chronic fatigue syndrome
- myalgic encephalomyelitis
- debilitating disease
- drug therapy
- other treatments